NXGL
NEXGEL, Inc.
There isn't enough reported data to score NXGL yet.
NXGL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
NXGL's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
NXGL PE Valuation
NXGL has no meaningful PE right now: it lost money over the past year.
NXGL Forward outlook
There aren't enough analyst estimates for NXGL to show an outlook.
NXGL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$14.20 | -$6.20 |
| Q1 2026 | -$8.00 | +$1.00 |
| Q4 2025 | -$7.60 | +$2.40 |
| Q3 2025 | -$7.40 | +$4.20 |
| Q2 2025 | -$8.00 | +$3.40 |
| Q1 2025 | -$9.00 | +$2.00 |
| Q4 2024 | -$10.00 | +$1.20 |
| Q3 2024 | -$11.60 | -$2.00 |
NXGL is still losing money, but far less than before: $14.20 per share over the past year, against $43.20 at its worst in late 2022.
NXGL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.7M | +28% |
| Q1 2026 | $2.7M | -5.6% |
| Q4 2025 | $2.8M | -8.1% |
| Q3 2025 | $2.9M | -0.2% |
| Q2 2025 | $2.9M | +100% |
| Q1 2025 | $2.8M | +122% |
| Q4 2024 | $3M | +181% |
| Q3 2024 | $2.9M | +141% |
NXGL's revenue has held roughly level: $4M last quarter, up 28% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -68% | -46 points |
| Q1 2026 | -36% | -8.5 points |
| Q4 2025 | -43% | -16 points |
| Q3 2025 | -25% | +2.1 points |
| Q2 2025 | -22% | +51 points |
| Q1 2025 | -28% | +41 points |
| Q4 2024 | -28% | +85 points |
| Q3 2024 | -27% | +23 points |
NXGL's operating margin was −68% last quarter, down 46 points from the same quarter a year ago.
NXGL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $241K | +$1.2M |
| Q3 2025 | -$793K | +$436K |
| Q4 2024 | -$928K | -$256K |
| Q3 2024 | -$1.2M | -$148K |
| Q2 2024 | -$909K | +$473K |
| Q1 2024 | -$1.2M | -$447K |
| Q4 2023 | -$672K | -$15K |
| Q3 2023 | -$1.1M | -$176K |
NXGL has burned cash in almost every quarter: −$3M over the past year, against −$4M the year before.
NXGL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.9% | +40.5K shares |
| 1 year | +18% | +67.9K shares |
| 3 years | +62% | +172K shares |
NXGL has 450,663 diluted shares, up 18% from a year ago.
NXGL Net Leverage
NXGL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NXGL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.8 | Neutral |
| Stochastic | 7.2 | Oversold |
NXGL's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
NXGL PE vs Healthcare Sector
NXGL has no meaningful PE right now: it lost money over the past year.
NXGL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.06 | 6.7% below |
| 20 week MA | $6.53 | 42% below |
| 50 week MA | $14.7 | 74% below |
| 100 week MA | $34.7 | 89% below |
| 200 week MA | $39.9 | 90% below |
NXGL is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
NXGL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $62.4 | $62.4 | 0% |
| 2022 | $62.4 | $27.2 | -56% |
| 2023 | $27.2 | $42.6 | +57% |
| 2024 | $42.6 | $94.0 | +121% |
| 2025 | $94.0 | $30.6 | -67% |
| 2026 YTD | $30.6 | $3.79 | -88% |
NXGL's yearly returns have swung widely, from +121% in 2024 to −67% in 2025. It's down 88% so far in 2026.